Development in [ * ] Indications; Lead Party Responsibilities. Subject to [ * ] the Development of [ * ] Activators in [ * ] Indications, for as long as [ * ] such Development, the Parties [ * ] with respect to Development activities for [ * ] Indications, except that:

Development Costs in [ * ] Indications. For all [ * ] Indications, subject to the [ * ] set forth in Section [ * ] Development Costs, provided that [ * ] Development Budget as approved by the JDC [ * ]. [ * ] pursuant to Section [ * ]. [ * ] Development Costs for [ * ] Indications, including the [ * ] Development activities [ * ] in the Shared Territory and [ * ] in Astellas Territory for [ * ] Activators in [ * ] Indications.

Other Indications. Subject to [Section 6.4.2], during the Term of this Agreement, neither Party, nor its respective Affiliates or Sublicensees, shall develop or commercialize [[Unknown Identifier]] for any and all indications outside of the Oncology Field.

Development in Other Indications. As of the Effective Date, the Parties intend to focus the Development of the Product in the Territory for HCM ​.

Development Costs in [ * ] Indications. If [ * ] with respect to a [ * ] Activator and subject to the [ * ] set forth in Section [ * ] for such [ * ], to the extent [ * ] Budget as approved by the JDC [ * ]. [ * ] pursuant to Section [ * ]. [ * ] Development Costs for the [ * ] Indications.

Licensed Indications and [ * ] Indications. At # any time after [ * ] Indication or [ * ] Indication, or # any time in connection with [ * ] Indication or any [ * ] Indication, [[Cytokinetics:Organization]] shall have the right to field its own MSLs in the Co-Promotion Territory (for Licensed Indications) or Shared Territory (for [ * ] Indications and [ * ] Indications), in connection with such Pivotal Registration Study. The percentage of total MSL deployment by [[Cytokinetics:Organization]] shall be agreed upon by the Parties, but in any event shall be no less than [ * ] and no more than [ * ]. If [[Cytokinetics:Organization]] exercises the [[Cytokinetics:Organization]] Co-Funding Option, the portion of the Medical Affairs Plan specific to such Collaboration Product for the [ * ] Indication(s) and any amendment thereto [ * ], and [[Cytokinetics:Organization]] may prepare [ * ]. If [[Cytokinetics:Organization]] exercises the option to Co-Promote pursuant to [Section 9.6] in any geographic region (i.e., Canada, the US, and EU plus Switzerland), [[Cytokinetics:Organization]] shall have the right to field MSLs [ * ] unless the Parties otherwise agree. Such MSLs of [[Cytokinetics:Organization]] shall perform certain Medical Affairs Activities allocated to them under the Medical Affairs Plan. Astellas shall reimburse the costs and expenses incurred by [[Cytokinetics:Organization]] in fielding the MSLs, which shall be calculated at a rate equal to [ * ].

Development in Other Indications. As of the Effective Date, the Parties intend to focus the Development of the Product in the Territory for HCM ​.

[ * ] Indications. If the JDC [ * ] a Collaboration Product in a [ * ] Indication after [ * ] then Astellas shall pay to [[Cytokinetics:Organization]]:

[ * ] Activators [ * ] Indications [ * ] notwithstanding Section [ * ] Indications [ * ] provided that [ * ] Development activities for a [ * ] Activator [ * ] Indication [ * ] Development under the Development Plan [ * ] Activator in any [ * ] Indication or any [ * ] Indication under this Agreement; and

LCM Indications. Viela may propose new LCM Indications to MTPC for Development and Commercialization pursuant to this Agreement by giving MTPC written notice of such proposal (“LCM Indication Notice”). MTPC will have ​ from MTPC’s receipt of the LCM Indication Notice to review the information and Viela will provide any additional information reasonably requested by MTPC during such review period. Upon or prior to the expiration of such review period, MTPC will notify Viela in writing of its decision to accept or reject such proposed LCM Indication. If MTPC rejects a proposed LCM Indication, # MTPC will provide in its written notice the reasoning in support of its conclusion, unless MTPC is legally prohibited from doing so, and # the Parties will discuss in good faith a plan to make such LCM Indication available to patients in the Territory.